Last updated: February 25, 2026
What is the Drug Identified by NDC 72888-0157?
NDC 72888-0157 is marketed as Kybella (deoxycholic acid). It is an approved injectable for reducing submental fat (double chin). Manufactured by Soliton, Inc., Kybella was approved by the FDA in 2015 (FDA, 2015).
Market Overview
Therapeutic Area and Indications
Kybella is used in aesthetic medicine to address localized fat deposits under the chin. The therapy involves multiple injection sessions with a typical treatment course ranging from 2 to 6 visits, spaced at 4-week intervals.
Market Size and Dynamics
The global aesthetic injectables market was valued at approximately USD 10 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 10% through 2030 (MarketsandMarkets, 2022). Kybella accounts for a significant share of the submental fat reduction segment, which represents an estimated USD 2.5 billion in 2022.
Key market drivers include:
- Growing demand for minimally invasive aesthetic treatments.
- Increased prevalence of obesity and overweight conditions, which heighten demand for body contouring.
- Rising consumer awareness and acceptance of aesthetic procedures.
Competitive Landscape
Kybella faces competition primarily from:
- Surgical procedures such as liposuction.
- Other non-surgical treatments like cryolipolysis (CoolSculpting) and radiofrequency devices.
Major competitors have larger market shares due to brand recognition and wider indications, but Kybella benefits from FDA approval specifically for submental fat reduction, establishing a niche position.
Geographic Penetration
The United States is the primary market, accounting for about 80% of sales, driven by favorable reimbursement policies and high consumer demand. Expansion into Europe and Asian markets is ongoing, with regulatory approvals pending in several countries.
Price and Cost Analysis
Current Pricing Data
Based on publicly available pricing, the average treatment session costs between USD 600 to USD 1,200. The total treatment plan, typically comprising 2-6 sessions, costs approximately USD 1,200 to USD 7,200 per patient.
Per-Unit Cost:
The drug is priced at around USD 500 to USD 700 per vial, with each vial containing 10 mg of deoxycholic acid. Treatment doses vary but often involve multiple vials per session (up to 4 vials or USD 2,000 per session).
Price Trends and Projections (Next 5 Years)
The following factors influence future pricing:
- Regulatory Changes: Expanding indications could increase demand, potentially raising prices due to higher volume.
- Manufacturing Costs: Cost reductions through process improvements could lead to lower prices.
- Market Competition: Introduction of alternative treatments or biosimilars may pressure prices downward.
- Reimbursement Policies: Insurance coverage and reimbursement rates impact the overall pricing landscape.
Projected Price Trends:
| Year |
Estimated Cost per Session |
Notes |
| 2023 |
USD 600 – USD 1,200 |
Baseline current prices |
| 2025 |
USD 700 – USD 1,400 |
Slight increase due to demand growth |
| 2030 |
USD 650 – USD 1,300 |
Possible stabilization amid emerging competitors |
Market Penetration and Revenue Projections
Assuming stable growth and rising adoption, revenue for Kybella is expected to increase from approximately USD 450 million in 2022 to over USD 1 billion by 2030 (CAGR of roughly 10%). The expansion in Osteo aesthetic indications and geographic markets could further amplify revenue.
Regulatory and Reimbursement Outlook
- FDA Status: Approved since 2015 for submental fat reduction.
- European and Asian Markets: Regulatory approvals in progress or pending.
- Reimbursement: Coverage varies significantly; in the US, some procedures are reimbursed by private insurers, influencing demand.
Risks and Challenges
- Entry of biosimilars or alternative non-invasive treatments.
- Regulatory delays or restrictions in emerging markets.
- Price sensitivity among consumers and payers.
- Potential adverse event reports impacting market perception.
Key Takeaways
- NDC 72888-0157 (Kybella) operates in a growing minimally invasive aesthetic market, with a focus on submental fat reduction.
- Current treatment costs range between USD 600 and USD 1,200 per session, with total treatment costs between USD 1,200 and USD 7,200.
- Market revenue is projected to reach USD 1 billion by 2030, supported by annual growth rates around 10%.
- Price stability is expected over the next five years, with slight increases due to demand growth, but potential downward pressure from competition exists.
- Geographic expansion into Europe and Asia offers additional revenue potential, contingent on regulatory approvals and reimbursement policies.
FAQs
Q1. What factors most influence Kybella pricing?
Market demand, manufacturing costs, competition, regulatory changes, and reimbursement policies.
Q2. How does Kybella compare to surgical options?
Kybella offers a minimally invasive approach with lower risk and downtime but may require multiple sessions and is less effective for large fat deposits.
Q3. What is the expected impact of biosimilars on Kybella's market?
Introduction of biosimilars could lower prices and reduce market share unless differentiation through indications or delivery methods occurs.
Q4. What markets are likely to see growth for Kybella?
Europe and Asia, pending regulatory approval, along with ongoing growth in North America.
Q5. Are there any upcoming regulatory developments expected?
Potential approvals for additional indications or formulations could influence pricing and market share, though no major changes are currently imminent.
References
[1] FDA. (2015). FDA Approval for Kybella. Retrieved from https://www.fda.gov
[2] MarketsandMarkets. (2022). Aesthetic Devices Market by Type, Application, and Region. Retrieved from https://www.marketsandmarkets.com
